On December 30, 2022, Pluristem Therapeutics, Inc closed the transaction. The company amended the terms of the transaction. The company has received $8,469,323 pursuant to exemption provided under Regulation D form 14 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 USD | -2.71% | +4.90% | +31.58% |
May. 09 | Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
May. 02 | Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment | CI |
1st Jan change | Capi. | |
---|---|---|
+31.58% | 32.87M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Inc. announced that it has received $8.469323 million in funding